Clinical Trial Update: Phase III, Long-term, Open-label Safety Study of Z-338 [Phase 3]

View source ↗

Summary

Phase III long-term open-label safety study of Z-338 has completed, reporting safety-focused data in individuals with dyspepsia. The update does not provide eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyspepsia

Drugs mentioned

• Z-338

Snippet

Sponsor: Zeria Pharmaceutical | Conditions: Dyspepsia | Phase 3 | Status: COMPLETED